Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 μg day-1) versus HFA-fluticasone propionate (1000 μg day-1) in patients with asthma

被引:38
作者
Aubier, M
Wettenger, R
Gans, SJM
机构
[1] Hop Bichat Claude Bernard, Serv Pneumol, F-75018 Paris, France
[2] Karl Hansen Klin, Bad Lippspringe, Germany
[3] Longarts, Harderwijk, Netherlands
关键词
HFA; hydrofluoroalkane; beclomethasone dipropionate; HFA-BDP; fluticasone; asthma;
D O I
10.1053/rmed.2000.1025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extra-fine aerosol and HFA-fluticasone propionate (HFA-FP) are chlorofluorocarbon-free inhalers. We conducted an 8-week, open study to demonstrate the equivalence of HFA-BDP (800 mug day(-1)) and HFA-FP (1000 mug day(-1)) in moderate to severe asthma. Symptomatic patients on 500-1000 mug day(-1) CFC-BDP (or equivalent) and short-acting beta -agonist, were randomized to HFA-BDP (n = 101) or HFA-FP (n = 97) after 7-14 (+/-2) day run-in. In the intent-to-treat (ITT) population (n = 198), both treatments provided clinically and statistically significant improvements in asthma control, with increases in peak expiratory flow in the morning (AM PEF) and asthma symptoms (within treatment analysis P<0.05). Mean (SE) change in AM PEF from baseline at week 8 was equivalent (defined as 90% CI for the mean difference between treatments within +/- 25 1 min(-1)) in the two groups: 29.59 (5.19) 1 min(-1) for HFA-BDP vs. 17.3 (5.45) 1 min(-1) for HFA-FP (90% CI-002, 24.91). For the per-protocol population (n = 121), the mean (SE) change in AM PEF from baseline was not equivalent; AM PEF improved to a significantly greater extent in the HFA-BDP group than HFA-FP group [34.84 (7.08) vs. 20.63 (7.32) 1 min(-1) P < 0.01; 90% CI: 2.66, 31.10]. At week 8 in the ITT population. there were no statistically significant differences in FEV1, beta -agonist use, asthma symptom/sleep disturbance scores, or percentage of days without asthma symptoms/sleep disturbance. There was a significantly greater reduction from baseline in mean eosinophil count for HFA-BDP compared with HFA-FP at weeks 3 and 8 (P < 0.01), and eosinophil cationic protein value at week 8 (P < 0.01). Both treatments were well tolerated and there were no statistically significant differences in urinary cortisol creatinine parameters. In conclusion, this study showed that, in patients with moderate-to-severe symptomatic asthma, HFA-BDP extra-fine aerosol 800 mug(-1) was at least as effective and equally well tolerated as 1000 mug day(-1) HFA-FP.
引用
收藏
页码:212 / 220
页数:9
相关论文
共 29 条
[1]  
AYRES J, 1995, EUR RESP J S19, V8, P157
[2]  
BARNES NC, 1993, EUR RESPIR J, V6, P877
[3]   Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less [J].
Barnes, NC ;
Hallett, C ;
Harris, TAJ .
RESPIRATORY MEDICINE, 1998, 92 (01) :95-104
[4]   Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant [J].
Busse, WW ;
Brazinsky, S ;
Jacobson, K ;
Stricker, W ;
Schmitt, K ;
Vanden Burgt, J ;
Donnell, D ;
Hannon, S ;
Colice, GL .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (06) :1215-1222
[5]  
Cohen R, 1999, AM J RESP CRIT CARE, V159, pA631
[6]  
Cohen R., 1998, European Respiratory Journal, V12, p80s
[7]  
CONWAY JH, 1999, EUR RESPIR J, V14, P1360
[8]  
CRIPPS AL, 1997, J AEROSOL MED, V10, P6
[9]   A DOSE-RANGING STUDY OF FLUTICASONE PROPIONATE IN ADULT PATIENTS WITH MODERATE ASTHMA [J].
DAHL, R ;
LUNDBACK, B ;
MALO, JL ;
MAZZA, JA ;
NIEMINEN, MM ;
SAARELAINEN, P ;
BARNACLE, H .
CHEST, 1993, 104 (05) :1352-1358
[10]   Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose [J].
Davies, RJ ;
Stampone, P ;
O'Connor, BJ .
RESPIRATORY MEDICINE, 1998, 92 :23-31